Global Swine Flu Vaccination Market Report 2024

The swine flu vaccination market size has grown strongly in recent years. It will grow from $13.01 billion in 2023 to $13.99 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historic period can be attributed to several factors, including the escalating prevalence of flu, declining immunity among the geriatric population, a rise in swine flu cases, government initiatives promoting immunization programs, and advancements in vaccine production and distribution.

The swine flu vaccination market size is expected to see strong growth in the next few years. It will grow to $18.76 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. Looking forward to the forecast period, the anticipated growth can be attributed to increasing demand for intramuscular vaccines, rising awareness of new vaccination technologies, a growing elderly population, the imperative for vaccinations to safeguard public health, and a heightened incidence of disease and pandemic episodes worldwide stemming from H1N1 infection. Key trends expected in the forecast period encompass technological advancements, expansions in business operations, product launches, strategic mergers and acquisitions, and partnerships among pharmaceutical firms.

Government initiatives aimed at vaccination programs are poised to drive the growth of the swine flu vaccination market in the coming years. These initiatives encompass policies and actions undertaken by governments to promote and facilitate vaccination campaigns, prioritizing immunization programs to effectively combat outbreaks and bolster public health efforts. For example, data from the Centers for Disease Control and Prevention in October 2021 indicated a significant increase in flu vaccination rates during the 2020-2021 season, with 50%-55% of adults receiving vaccination compared to 48% in the previous year. Additionally, the government's allocation of 9.3 million doses of adult influenza vaccine to establish a stockpile underscores the commitment to addressing supply issues. Hence, the escalating government initiatives toward vaccination programs are propelling the growth of the swine flu vaccination market.

Key players in the swine flu vaccination market are concentrating on developing innovative products such as the quadrivalent influenza vaccine to strengthen their market position. The quadrivalent influenza vaccine is designed to protect against four different influenza virus strains, offering enhanced protection compared to traditional vaccines. For instance, in March 2024, Cadila Pharmaceuticals launched Cadiflu Tetra, a cutting-edge quadrivalent influenza vaccine targeting four influenza virus subtypes A and B strains. Utilizing nano-sized particle technology, Cadiflu Tetra mimics the virus's external structure, enhancing efficacy and safety without containing intact genetic material. This advanced approach provides improved protection against multiple influenza strains, offering a technologically superior solution for preventing seasonal epidemics.

In September 2021, Vaxxinova acquired Newport Laboratories from Boehringer Ingelheim, aiming to expand its portfolio of custom-made vaccines for swine and cattle. Newport Laboratories, a US-based company, specializes in manufacturing custom-made vaccines and holds intellectual property rights related to the development of swine flu vaccines for pigs. With this acquisition, Vaxxinova seeks to provide a more comprehensive range of solutions to its customers in the animal health sector, further strengthening its position in the market.

Major companies operating in the swine flu vaccination market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Mylan N.V., Moderna Inc., Baxter International Inc., Zoetis Inc., Elanco Animal Health, Cipla Inc., Lupin Ltd., Virbac S.A, Sinovac Biotech Ltd., Serum Institute of India Private Limited., Vetoquinol S.A, IDT Biologika GmbH, Bharat Biotech International Limited, Medicago Inc., Panacea Biotec, Hipra.

North America was the largest region in the swine flu vaccination market in 2023. The regions covered in the swine flu vaccination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the swine flu vaccination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Swine flu vaccination refers to vaccines formulated to safeguard against influenza viruses commonly found in pigs (swine flu). These vaccines are developed with the aim of preventing the transmission of swine flu from pigs to humans.

Within the swine flu vaccination market, the primary vaccine types include intranasal, toxoid, conjugate, inactivated vaccine, attenuated vaccine, and others. An intranasal vaccine is administered through the nasal passages, stimulating the immune system to guard against specific diseases by introducing weakened or deactivated pathogens. Various treatment types encompass influenza, meningococcal, cervical cancer, pneumococcal, hepatitis, measles, mumps, rubella, and others. These treatments are utilized across a spectrum of end-users, including hospitals, clinics, and other healthcare facilities.

The swine flu vaccination market research report is one of a series of new reports that provides swine flu vaccination market statistics, including swine flu vaccination industry global market size, regional shares, competitors with a swine flu vaccination market share, detailed swine flu vaccination market segments, market trends, and opportunities, and any further data you may need to thrive in the swine flu vaccination industry. This swine flu vaccination market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The swine flu vaccination market includes revenues earned by entities by vaccine administration, assessment and screening, documentation and record-keeping, and follow-up and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The swine flu vaccination market consists of sales of fluMist quadrivalent, FluLaval quadrivalent, Fluzone quadrivalent, and afluria quadrivalent. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.